The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition

Journal of Neurochemistry

Volumn 115, Issue 1, 2010, Pages 36-46

  Covy, Jason P ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

kinase; leucine rich repeat kinase 2; magnesium; manganese; Parkinson disease

Indexed keywords

ADENOSINE TRIPHOSPHATE; LEUCINE RICH REPEAT KINASE 2; MAGNESIUM; MANGANESE; METAL ION; LRRK2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RECOMBINANT PROTEIN;

ARTICLE; CATALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MUTATION; PARKINSON DISEASE; PRIORITY JOURNAL; STOICHIOMETRY; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KINETICS; METABOLISM; MOLECULAR GENETICS; PHOSPHORYLATION; PHYSIOLOGY; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; BLOTTING, WESTERN; CATALYSIS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; KINETICS; MAGNESIUM; MANGANESE; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS;

EID: 77956599277     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06894.x     Document Type: Article

References (63)

1. Anand V. S., Reichling L. J., Lipinski K. et al. (2009) Investigation of leucine-rich repeat kinase 2:enzymological properties and novel assays. FEBS J. 276, 466 478.
2. Au C., Benedetto A. Aschner M. (2008) Manganese transport in eukaryotes: the role of DMT1. Neurotoxicology 29, 569 576.
3. Biskup S. West A. B. (2008) Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim. Biophys. Acta 1778, 1881 1896.
4. Biskup S., Gerlach M., Kupsch A., Reichmann H., Riederer P., Vieregge P., Wullner U. Gasser T. (2008) Genes associated with Parkinson syndrome. J. Neurol. 255 (Suppl. 5 8 17.
5. Bonifati V. (2007) Genetics of parkinsonism. Parkinsonism Related Disord. 13 (Suppl. 3 S233 S241.
6. Chen C. A. Okayama H. (1997) High-efficient transfection using calcium phosphate-DNA precipitate formed in BES, in Current Protocols in Molecular Biology (Ausubel F. M., Brent R., Kingston R. E., Moore D. D., Seidman J. G., Smith J. A. Struhl K., eds pp. 917 919. John Wiley & Sons, Inc., New York.
7. Courtneidge S. A. (1985) Activation of the pp60c-src kinase by middle T antigen binding or by dephosphorylation. EMBO J. 4, 1471 1477.
8. Covy J. P. Giasson B. I. (2009) Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem. Biophys. Res. Commun. 378, 473 477.
9. De Bondt H. L., Rosenblatt J., Jancarik J., Jones H. D., Morgan D. O. Kim S. H. (1993) Crystal structure of cyclin-dependent kinase. Nature 363, 595 602.
10. Deng H., Le W., Guo Y., Hunter C. B., Xie W. Jankovic J. (2005) Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann. Neurol. 57, 933 934.
11. Di Fonzo A., Rohe C. F., Ferreira J. et al. (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365, 412 415.
12. Dobson A. W., Erikson K. M. Aschner M. (2004) Manganese neurotoxicity. Ann. NY Acad. Sci. 1012, 115 128.
13. Elberg G., Li J., Leibovitch A. Shechter Y. (1995) Non-receptor cytosolic protein tyrosine kinases from various rat tissues. Biochim. Biophys. Acta 1269, 299 306.
14. Forman M. S., Lee V. M. Trojanowski J. Q. (2005) Nosology of Parkinson's disease: looking for the way out of a quackmire. Neuron 47, 479 482.
15. Giasson B. I. Van Deerlin V. M (2008) Mutations in LRRK2 as a cause of Parkinson's disease. Neurosignals 16, 99 105.
16. Gilks W. P., Abou-Sleiman P. M., Gandhi S. et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415 416.
17. Gloeckner C. J., Kinkl N., Schumacher A., Braun R. J., O'Neill E., Meitinger T., Kolch W., Prokisch H. Ueffing M. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223 232.
18. Gloeckner C. J., Schumacher A., Boldt K. Ueffing M. (2009) The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J. Neurochem. 109, 959 968.
19. Greggio E. Cookson M. R. (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1.
20. Greggio E., Jain S., Kingsbury A. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329 341.
21. Greggio E., Zambrano I., Kaganovich A. et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 283, 16906 16914.
22. Hanks S. K., Quinn A. M. Hunter T. (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42 52.
23. Henchcliffe C. Beal M. F. (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 4, 600 609.
24. Hernandez D., Paisan R. C., Crawley A., Malkani R., Werner J., Gwinn-Hardy K., Dickson D., Wavrant D. F., Hardy J. Singleton A. (2005) The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci. Lett. 389, 137 139.
25. Hoehn M. M. Yahr M. D. (1967) Parkinsonism: onset, progression and mortality. Neurology 17, 427 442.
26. Huang C. Y., Yuan C. J., Luo S. Graves D. J. (1994) Mutational analyses of the metal ion and substrate binding sites of phosphorylase kinase gamma subunit. Biochemistry 33, 5877 5883.
27. Hunter T. Cooper J. A. (1985) Protein-tyrosine kinases. Annu. Rev. Biochem. 54, 897 930.
28. Jaleel M., Nichols R. J., Deak M., Campbell D. G., Gillardon F., Knebel A. Alessi D. R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405, 307 317.
29. Kachergus J., Mata I. F., Hulihan M. et al. (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76, 672 680.
30. Kannan N. Neuwald A. F. (2005) Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? J. Mol. Biol. 351, 956 972.
31. Karlsson R., Zheng J., Xuong N., Taylor S. S. Sowadski J. M. (1993) Structure of the mammalian catalytic subunit of cAMP-dependent protein kinase and an inhibitor peptide displays an open conformation. Acta Crystallogr. D Biol. Crystallogr. 49, 381 388.
32. Knowles J. R. (1980) Enzyme-catalyzed phosphoryl transfer reactions. Annu. Rev. Biochem. 49, 877 919.
33. Koland J. G. Cerione R. A. (1990) Activation of the EGF receptor tyrosine kinase by divalent metal ions: comparison of holoreceptor and isolated kinase domain properties. Biochim. Biophys. Acta 1052, 489 498.
34. Kornev A. P., Haste N. M., Taylor S. S. Eyck L. F. (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl Acad. Sci. USA 103, 17783 17788.
35. Lesage S., Ibanez P., Lohmann E. et al. (2005) G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann. Neurol. 58, 784 787.
36. Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A. L., Janin S., Pollak P. Brice A. (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354, 422 423.
37. Levinson N. M., Kuchment O., Shen K., Young M. A., Koldobskiy M., Karplus M., Cole P. A. Kuriyan J. (2006) A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol. 4, e144.
38. Lovitt B., Vanderporten E. C., Sheng Z., Zhu H., Drummond J. Liu Y. (2010) Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase-2 (LRRK2). Biochemistry 49, 3092 3100.
39. Luzon-Toro B., Rubio de la T. E., Delgado A., Perez-Tur J. Hilfiker S. (2007) Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum. Mol. Genet. 16, 2031 2039.
40. Manning G., Whyte D. B., Martinez R., Hunter T. Sudarsanam S. (2002) The protein kinase complement of the human genome. Science 298, 1912 1934.
41. Mata I. F., Wedemeyer W. J., Farrer M. J., Taylor J. P. Gallo K. A. (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29, 286 293.
42. Nichols W. C., Pankratz N., Hernandez D. et al. (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365, 410 412.
43. Nichols R. J., Dzamko N., Hutti J. E., Cantley L. C., Deak M., Moran J., Bamborough P., Reith A. D. Alessi D. R. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem. J. 424, 47 60.
44. Ozelius L. J., Senthil G., Saunders-Pullman R. et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354, 424 425.
45. Paisan-Ruiz C., Jain S., Evans E. W. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595 600.
46. Paisan-Ruiz C., Lang A. E., Kawarai T., Sato C., Salehi-Rad S., Fisman G. K., Al Khairallah T., George-Hyslop P., Singleton A. Rogaeva E. (2005) LRRK2 gene in Parkinson disease. Neurology 65, 696 700.
47. Perl D. P. Olanow C. W. (2007) The neuropathology of manganese-induced Parkinsonism. J. Neuropathol. Exp. Neurol. 66, 675 682.
48. Puli S., Lai J. C. K., Edgley K. L., Daniels C.K. Bhushan A. (2006) Signaling pathways mediating manganese-induced toxicity in human glioblastoma cells (U87). Neurochem. Res. 31, 1211 1218.
49. Reichling L. J. Riddle S. M. (2009) Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. Biochem. Biophys. Res. Commun. 384, 255 258.
50. Ross O. A. Farrer M. J. (2005) Pathophysiology, pleotrophy and paradigm shifts: genetic lessons from Parkinson's disease. Biochem. Soc. Trans. 33, 586 590.
51. Saylor P., Wang C., Hirai T. J. Adams J. A. (1998) A second magnesium ion is critical for ATP binding in the kinase domain of the oncoprotein v-Fps. Biochemistry 37, 12624 12630.
52. Simuni T. Hurtig H. I. (2000) Parkinson's disease: the clinical picture, in Neurodegenerative dementias (Clark C. M. Trojanoswki J. Q., eds pp. 193 203. McGraw-Hill, New York.
53. Smith W. W., Pei Z., Jiang H., Dawson V. L., Dawson T. M. Ross C. A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231 1233.
54. Sun G. Budde R. J. (1997) Requirement for an additional divalent metal cation to activate protein tyrosine kinases. Biochemistry 36, 2139 2146.
55. Taylor S. S. Radzio-Andzelm E. (1994) Three protein kinase structures define a common motif. Structure 2, 345 355.
56. Taylor J. P., Mata I. F. Farrer M. J. (2006) LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol. Med. 12, 76 82.
57. Thomas B. Beal M. F. (2007) Parkinson's disease. Hum. Mol. Genet. 16 (Spec No. 2 R183 R194.
58. Toru-Delbauffe D., Pierre M., Osty J., Chantoux F. Francon J. (1986) Properties of neurofilament protein kinase. Biochem. J. 235, 283 289.
59. Webber P. J. West A. B. (2009) LRRKS in Parkinson's disease: function in cells and neurodegeneration. FEBS Lett. 276, 6436 6444.
60. West A. B., Moore D. J., Biskup S., Bugayenko A., Smith W. W., Ross C. A., Dawson V. L. Dawson T. M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl. Acad. Sci. USA 102, 16842 16847.
61. West A. B., Moore D. J., Choi C. et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223 232.
62. Yuan C. J., Huang C. Y. Graves D. J. (1993) Phosphorylase kinase, a metal ion-dependent dual specificity kinase. J. Biol. Chem. 268, 17683 17686.
63. Zimprich A., Biskup S., Leitner P. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601 607.